Biodexa Pharmaceuticals (BDRX) Cash from Restructuring (2015)
Biodexa Pharmaceuticals (BDRX) reported Cash from Restructuring of -$3.8 million for Q4 2015.
Biodexa Pharmaceuticals (BDRX) Cash from Restructuring (2015) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 1 years of Cash from Restructuring data on file, last reported at -$3.8 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Biodexa Pharmaceuticals | 17.77 Bn | 17.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -3.84 Mn |